Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Berger

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod WithdrawalFabien Rollot, Justine Couturier, Romain Casey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2025
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French populationElisabeth Maillart, Fabien Rollot, Emmanuelle Leray, et al.
Neurology|July 11, 2024
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 StudyRomain Deschamps, Jessica Guillaume, Jonathan Ciron, et al.
European Journal of Neurology|March 2, 2021
Untreated patients with multiple sclerosis: A study of French expert centersXavier Moisset, Audrey-Anne Fouchard, Bruno Pereira, et al.
Journal of Alzheimer'S Disease : JAD|December 21, 2012
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testingIsabelle Le Ber, Agnès Camuzat, Lena Guillot-Noel, et al.
Multiple Sclerosis and Related Disorders|May 14, 2026
External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims databaseLaure Carcaillon-Bentata, Abdelilah Abouelfath, Séverine Lignot-Maleyran, et al.
Neurology|November 6, 2016
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathyBéatrice Pignolet, Nicholas Schwab, Tilman Schneider-Hohendorf, et al.
Neurology|September 25, 2024
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life StudyMarion Hay, Fabien Rollot, Romain Casey, et al.
JAMA Network Open|October 11, 2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated SyndromeChristine Lebrun-Frénay, Fabien Rollot, Lydiane Mondot, et al.
JAMA Neurology|September 4, 2019
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in FranceSandra Vukusic, Fabien Rollot, Romain Casey, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod WithdrawalFabien Rollot, Justine Couturier, Romain Casey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2025
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French populationElisabeth Maillart, Fabien Rollot, Emmanuelle Leray, et al.
Neurology|July 11, 2024
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 StudyRomain Deschamps, Jessica Guillaume, Jonathan Ciron, et al.
European Journal of Neurology|March 2, 2021
Untreated patients with multiple sclerosis: A study of French expert centersXavier Moisset, Audrey-Anne Fouchard, Bruno Pereira, et al.
Journal of Alzheimer'S Disease : JAD|December 21, 2012
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testingIsabelle Le Ber, Agnès Camuzat, Lena Guillot-Noel, et al.
Multiple Sclerosis and Related Disorders|May 14, 2026
External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims databaseLaure Carcaillon-Bentata, Abdelilah Abouelfath, Séverine Lignot-Maleyran, et al.
Neurology|November 6, 2016
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathyBéatrice Pignolet, Nicholas Schwab, Tilman Schneider-Hohendorf, et al.
Neurology|September 25, 2024
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life StudyMarion Hay, Fabien Rollot, Romain Casey, et al.
JAMA Network Open|October 11, 2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated SyndromeChristine Lebrun-Frénay, Fabien Rollot, Lydiane Mondot, et al.
JAMA Neurology|September 4, 2019
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in FranceSandra Vukusic, Fabien Rollot, Romain Casey, et al.
Pageof 13